Effect of different melphalan formulation pretreatment on the incidence and severity of diarrhea in patients with lymphoid tumors undergoing autologous hematopoietic stem cell transplantation
10.12025/j.issn.1008-6358.2026.20260287
- VernacularTitle:不同美法仑制剂预处理对淋巴肿瘤自体造血干细胞移植患者腹泻发生率及严重程度的影响
- Author:
Peiying ZHUANG
1
;
Danxia LIN
2
;
Yuemei CHEN
1
;
Zheng WEI
3
Author Information
1. Department of Nursing, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, Fujian, China.
2. Department of Hematology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, Fujian, China.
3. Department of Hematology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, Fujian, China;Xiamen Key Laboratory of Biotherapy, Xiamen 361015, Fujian, China;Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province, Xiamen 361015, Fujian, China;Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, Fujian, China.
- Publication Type:Shortarticle
- Keywords:
melphalan;
autologous hematopoietic stem cell transplantation;
diarrhea;
gastrointestinal adverse reaction;
propylene glycol
- From:
Chinese Journal of Clinical Medicine
2026;33(5):851-857
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the differences in the incidence and severity of diarrhea between patients receiving propylene glycol-melphalan (PG-MEL) or propylene glycol-free-melphalan (PGF-MEL) pretreatment during autologous hematopoietic stem cell transplantation (AHSCT). Methods The clinical data of 30 patients who underwent AHSCT with high-dose melphalan (HDM) pretreatment at the Department of Hematology, Zhongshan Hospital (Xiamen), Fudan University, from January 2024 to November 2025 were retrospectively analyzed. Patients were divided into the PG-MEL group (n＝15) and the PGF-MEL group (n＝15) according to the formulation. The incidence, onset time, maximum daily frequency, duration, type, and severity of diarrhea were compared between the two groups. Oral mucositis, vomiting, infection, fever, and other related adverse events, as well as hematopoietic recovery, were also observed. Results The overall incidence of diarrhea was 93.3% in both groups. There was no significant difference in the onset time of diarrhea between the two groups ([4.0±2.0] d vs [3.0±2.0] d). Compared with the PG-MEL group, the PGF-MEL group had a higher maximum daily frequency of diarrhea (8 [6,14] times vs 6 [4,6] times, P＝0.009), a higher proportion of grade 3–4 diarrhea (57.1% vs 14.3%, P＝0.046), and a longer duration of diarrhea ([8.0±4.0] d vs [5.0±2.0] d, P＝0.033). No statistically significant differences were observed between the two groups in the incidence of other adverse events such as oral mucositis, vomiting, infection, fever, or neutrophil and platelet engraftment times. Conclusions PG-MEL and PGF-MEL showed the same overall incidence of diarrhea in AHSCT. However, the PGF-MEL group experienced more severe diarrhea and longer duration. There were no significant differences between the two formulations in other adverse reactions or short-term transplant outcomes.
